Racura Oncology Ltd
RAC
Company Profile
Business description
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
Contact
1 Macquarie Place
Level 36
Gateway
SydneyNSW2000
AUST: +61 280513043
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
Stocks News & Analysis
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
stocks
The most popular ASX trades in FY26
A closer look at the stocks and ETFs that captured Aussie investors’ attention in FY26.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,974.20 | 85.30 | -0.94% |
| CAC 40 | 8,299.09 | 138.80 | -1.64% |
| DAX 40 | 24,763.12 | 392.29 | -1.56% |
| Dow JONES (US) | 51,711.65 | 506.93 | -0.97% |
| FTSE 100 | 10,639.17 | 77.80 | -0.73% |
| HKSE | 25,210.81 | 318.15 | 1.28% |
| NASDAQ | 25,137.69 | 553.21 | -2.15% |
| Nikkei 225 | 65,290.10 | 1,132.50 | -1.70% |
| NZX 50 Index | 13,763.32 | 31.99 | -0.23% |
| S&P 500 | 7,408.30 | 90.66 | -1.21% |
| S&P/ASX 200 | 8,795.70 | 81.90 | -0.92% |
| SSE Composite Index | 3,876.78 | 9.74 | 0.25% |